Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 1
1948 3
1949 1
1950 1
1964 1
1976 1
1981 1
1986 1
1990 1
1991 2
1992 1
1993 1
1994 3
1995 7
1996 4
1997 3
1998 3
1999 2
2001 3
2002 1
2003 4
2004 7
2006 2
2007 4
2008 6
2009 14
2010 7
2011 9
2012 3
2013 7
2014 3
2015 8
2016 15
2017 10
2018 21
2019 15
2020 13
2021 17
2022 12
2023 18
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
Graves' disease.
Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, Eckstein AK, Stagnaro-Green A, Kahaly GJ. Davies TF, et al. Among authors: eckstein ak. Nat Rev Dis Primers. 2020 Jul 2;6(1):52. doi: 10.1038/s41572-020-0184-y. Nat Rev Dis Primers. 2020. PMID: 32616746 Review.
Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Douglas RS, et al. Among authors: eckstein a. N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434. N Engl J Med. 2020. PMID: 31971679 Clinical Trial.
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ. Douglas RS, et al. Among authors: eckstein a. Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21. Ophthalmology. 2022. PMID: 34688699 Free article. Clinical Trial.
[Editorial].
Eckstein A, Heindl LM, Hintschich C. Eckstein A, et al. Klin Monbl Augenheilkd. 2022 Jan;239(1):17-18. doi: 10.1055/a-1685-2128. Epub 2022 Feb 4. Klin Monbl Augenheilkd. 2022. PMID: 35120373 German. No abstract available.
[Editorial].
Eckstein A, Heindl L. Eckstein A, et al. Klin Monbl Augenheilkd. 2024 Jan;241(1):8-9. doi: 10.1055/a-2169-6091. Epub 2024 Jan 19. Klin Monbl Augenheilkd. 2024. PMID: 38242134 German. No abstract available.
[Graves' orbitopathy].
Eckstein A, Möller L, Führer D, Oeverhaus M. Eckstein A, et al. Dtsch Med Wochenschr. 2021 Oct;146(20):1344-1351. doi: 10.1055/a-1239-2792. Epub 2021 Oct 13. Dtsch Med Wochenschr. 2021. PMID: 34644795 Review. German.
Sphingolipids in thyroid eye disease.
Gulbins A, Görtz GE, Gulbins E, Eckstein A. Gulbins A, et al. Among authors: eckstein a. Front Endocrinol (Lausanne). 2023 Apr 4;14:1170884. doi: 10.3389/fendo.2023.1170884. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37082124 Free PMC article. Review.
[Graves' ophthalmopathy].
Eckstein A, Dekowski D, Führer-Sakel D, Berchner-Pfannschmidt U, Esser J. Eckstein A, et al. Ophthalmologe. 2016 Apr;113(4):349-64; quiz 465-6. doi: 10.1007/s00347-016-0239-3. Ophthalmologe. 2016. PMID: 27059986 Review. German.
220 results